Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
European Institute of Oncology, Milan, Italy. Electronic address: [email protected]
Departments of Medical Sciences and Endocrine Oncology, Uppsala University, Uppsala, Sweden.
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital University of Oxford, Oxford, England.
Novartis Pharmaceuticals Corp, Florham Park, NJ.
Cedars-Sinai Medical Center, Los Angeles, CA.
- Published Article
- Publication Date
ClinicalTrials.gov; No.: NCT00412061
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/23187897